Of note, circSEMA4B inhibited the activation of PI3K/AKT signaling pathway by encoding the novel protein SEMA4B-211aa and sponging miR-330-3p, indicating it function as a valuable therapeutic target for BC treatment. This evidence concerns the gene SEMA4B and breast cancer.